Med Life Sa · BVB:M
Med Life Sa — Q1 2022 Earnings Presentation
16 slides from Med Life Sa's earnings presentation, May 13, 2022
Slide 1: Q1 2022 Financial Results presentation
Q1 2022 Financial Results presentation Divizia Spitale Strategie de comunicare 2022 13 May 2022 www.medlife.ro
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Snapshot Highlights 3m 2022 • Key messages • Outlook AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 3m 2022
Highlights 3m 2022 • Snapshot • Key messages • Outlook 1 4/
Slide 5: Snapshot
Snapshot ➢ Pro-forma consolidated Sales of RON 431m in Q1 2022, increased by 28% compared to Q1 2021; ➢ IFRS consolidated Sales of RON 419m in Q1 2022, increased by 24% compared to Q1 2021 (5% like to like increase on one-off COVID demand in Q1 2021); ➢ Sales growth sustained equally by traffic incr
Slide 6: Key messages 3m 2022
Key messages 3m 2022 ➢ In 2022, MedLife Group continued its dynamic strategy of expansion through acquisitions and finalized the acquisition of Neolife and OncoCard, consolidating the most powerful oncology and radiotherapy services platform in Romania; ➢ The Group followed through its strategy of r
Slide 7: Outlook for 2022 and years to come
Outlook for 2022 and years to come ➢ Pursue a balanced approach, both from a medical and business perspective, with further consolidation of inpatient services for acute diseases & oncological diagnostic and treatment services; these are conditions that cannot be postponed to the next economic cycle
Slide 8: Outlook for 2022 and years to come
Outlook for 2022 and years to come ➢ The next stage of development of this medical hub is planned for 2023 when MedLife intends to put into operation new surgery rooms and expand the hospitalization capacity of the largest hospital in the group with another 150 beds; ➢ MedLife Park pilot project wil
Slide 9: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 9/
Slide 10: Consolidated Statement of Profit and Loss
3m 2022 Pro-forma vs. 3m 2021 IFRS Consolidated Statement of Profit and Loss ❑ Sales increased by 27.6%, to RON 431m; ❑ OPEX increased by 36.6%, to RON 389m; ❑ 16.7% decrease in EBIT, to 44.7m RON, leading to 10.4% pro-forma margin (15.9% in the same period last year) mainly following decrease in PC
Slide 11: Operational KPIs – business lines evolution and bridge to pro-forma figures
Operational KPIs –business lines evolution and bridge to pro-forma figures ❑ On a pro-forma basis, Clinics remain the main sales unit of the group, with 35% share in total Sales: growth sustained mainly by increased traffic in all outpatient units and new acquisitions performed; ❑ Hospitals with 18.
Slide 12: OPEX evolution
OPEX evolution Decrease of 6.5 p.p. in EBITDA margin due to: ➢ Decrease in Consumable materials and repair materials with 3.8 p.p. of Sales due to significant decrease in PCR testing and Pharmachem consolidation; ➢ Increase in Commodities with 9.5 p.p. of Sales due to consolidation of CED Pharma Gro
Slide 13: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position 13 /
Slide 14: Debt position
Debt position Leasing liabilities December 31, March 31, on 2021 2022 7#VAR IFRS IFRS current portion - leasing 52,586,827 57,311,664 9.0% long term portion - leasing 149,685,246 154,252,955 3.1% Total 202,272,073 211,564,619 4.6% Financial debt December 31, March 31, 5 %VAR 2021 2022 IFRS IFRS Over
Slide 15: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow ❑ Strong cash flow from operations before working capital changes at RON 71m; ❑ 4 X increase in investments YoY, to RON 78.9m mainly due to investment in business combination; ❑ Net cash from financing activities of RON 49.5m RON. 15 /
Slide 16: Q&A Session Thank you!
Q&A Session Thank you! 3 16 /